Comparative Pharmacology
Head-to-head clinical analysis: INGREZZA versus VALBENAZINE TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGREZZA versus VALBENAZINE TOSYLATE.
INGREZZA vs VALBENAZINE TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. By inhibiting VMAT2, it reduces the uptake of monoamines into synaptic vesicles, thereby decreasing presynaptic dopamine concentrations and mitigating dopaminergic hyperactivity associated with tardive dyskinesia.
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
Initial dose: 6 mg orally twice daily; may increase to 12 mg twice daily based on response.
None Documented
None Documented
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
The terminal elimination half-life of valbenazine is approximately 15–22 hours for the parent drug and 20–25 hours for its active metabolite, (+)-α-dihydrotetrabenazine (dihydrotetrabenazine). The long half-life supports once-daily dosing.
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
Approximately 73% of the dose is excreted in feces (primarily as parent drug and metabolites) and 20% in urine. The major metabolites are valbenazine glucuronide and its acid metabolite.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor